Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

from discontinued operations of Atrium of nearly $26 million.

CONFERENCE CALL

Management will be hosting a conference call for the investment community beginning at 10:00 a.m. Eastern Time today, Wednesday, March 5, to discuss fourth quarter and full-year 2007 results.

To participate in the live conference call by telephone, please dial 416-644-3425, 514-807-8791 or 800-595-8550. Individuals interested in listening to the conference call on the Internet may do so by visiting http://www.aezsinc.com. A replay will be available on the Company's Web site for 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CASTLE ROCK, Colo. , May 23, 2013 /PRNewswire/ ... vitro diagnostic company focused on obtaining FDA clearance ... APPY1 , today announced the pricing of an underwritten ... and related warrants to purchase 3,500,000 shares of its ... share at a combined public offering price of $1.25 ...
(Date:5/23/2013)... 2013 PuraMed BioScience ® , Inc., ... over-the-counter (OTC) medicinal and healthcare products, announced that ... company based on low market capitalization valuation. ... Natural Product to Treat Migraine Headaches , ... Competitor , Currently Available Nationwide at Walgreen,s ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical Center ... became the first hospital on the West Coast to ... new surgical option provides women with a state-of-the-art, minimally ... Marc Winter , M.D., a highly regarded ... and medical director of minimally invasive surgery at Saddleback ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... , PLYMOUTH MEETING, Pa. , May ... or the "Company") today announced,financial results for the first quarter ended ... , ... BMP Sunstone, stated, "This was a,quarter of successful management transition at Sunstone. ...
... May 10 JHP Pharmaceuticals, sterile manufacturing site based ... Manufacturing Practices)/Pre Approval Audit by the U.S. Food and Drug ... GMP audits in 2009 including an audit by the FDA ... Agency (EMEA), which resulted in a continuance of the certificate ...
... May 10 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC Bulletin Board: CHME) ... pharmaceuticals, traditional Chinese medicine,products, other nutraceuticals, medical devices, and medical formulations,today announced ... on Thursday, May 13, 2010 to discuss its first ... , ...
Cached Biology Technology:BMP Sunstone Reports First Quarter 2010 Financial Results 2BMP Sunstone Reports First Quarter 2010 Financial Results 3BMP Sunstone Reports First Quarter 2010 Financial Results 4BMP Sunstone Reports First Quarter 2010 Financial Results 5BMP Sunstone Reports First Quarter 2010 Financial Results 6BMP Sunstone Reports First Quarter 2010 Financial Results 7BMP Sunstone Reports First Quarter 2010 Financial Results 8BMP Sunstone Reports First Quarter 2010 Financial Results 9BMP Sunstone Reports First Quarter 2010 Financial Results 10BMP Sunstone Reports First Quarter 2010 Financial Results 11BMP Sunstone Reports First Quarter 2010 Financial Results 12JHP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits 2China Medicine Announces Conference Call to Discuss First Quarter 2010 Results 2
(Date:5/23/2013)... succeeded in treating cerebral palsy with autologous cord blood. ... 2.5 year old boy had been in a persistent ... two months after treatment with the cord blood containing ... months, the child learned to speak simple sentences and ... Korean study, dispel the long-held doubts about the effectiveness ...
(Date:5/23/2013)... largest and fastest growing open-access publishers, announces the ... Bioengineering and Biotechnology . , A broad ... Bioengineering and Biotechnology will provide a single ... biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web platform ...
(Date:5/23/2013)... an age when microbial pathogens are growing increasingly resistant ... a team of Wisconsin scientists has synthesized a potent ... that cause staph infections. , Writing online in the ... group led by University of Wisconsin-Madison chemistry Professor Helen ... sensing" behavior of Staphylococcus aureus , a bacterium ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2
... the genomes of malaria parasites and humans have been at ... collaboration with an international team of scientists, have developed a ... fought back. The international team was led ... in the genetics department in Penn,s Perelman School of Medicine ...
... the Biotechnology and Biological Sciences Research Council (BBSRC)-led Integrated ... enzyme in bacteria which could be used to make ... the 14 June Issue of the American Chemical Society ... by teams at the Universities of Warwick and British ...
... Researchers at North Carolina State University have ... more efficiently, significantly enhancing a computer,s ability to ... improved the efficiency of algorithms used to build ... more realistic models that can account for uncertainty ...
Cached Biology News:Penn researchers show new evidence of genetic 'arms race' against malaria 2Penn researchers show new evidence of genetic 'arms race' against malaria 3First wood-digesting enzyme found in bacteria could boost biofuel production 2New parallelization technique boosts our ability to model biological systems 2
... Obtain Clean and Accurate Results ... to dramatically increase the sensitivity and accuracy ... of homogeneous cell types and multi-cellular structures ... This unique approach to microdissection-developed in 1996 ...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
... raised against a partial recombinant ... K6HF (NP_004684, 141 a.a. ... protein with GST tag. ... NM_004693 Protein ...
... DNA Visualizer DX's sensitivity of DNA detection has ... band in an agarose gel can be detected ... kit can be purified by organic solvent extraction ... commercially kits worked well.) DNA excised from ...
Biology Products: